- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 633KB)
Daratumumab – March 2023
Daratumumab: Solution for I.V. infusion 100 mg in 5 mL vial, Solution for I.V. infusion 400 mg in 20 mL vial, Solution for S.C. injection 1,800 mg in 15 mL vial; Darzalex®
Last updated
14 July 2023